Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Imagenebio Inc (IMA)

Imagenebio Inc (IMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,274
  • Shares Outstanding, K 11,182
  • Annual Sales, $ 3,500 K
  • Annual Income, $ -49,230 K
  • EBIT $ -59 M
  • EBITDA $ -60 M
  • 60-Month Beta 0.43
  • Price/Sales 97.84
  • Price/Cash Flow N/A
  • Price/Book 0.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.45
  • Number of Estimates 3
  • High Estimate -1.15
  • Low Estimate -1.61
  • Prior Year -2.16
  • Growth Rate Est. (year over year) +32.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.19 +13.09%
on 01/21/26
7.60 -7.89%
on 01/30/26
+0.70 (+11.11%)
since 01/20/26
3-Month
5.70 +22.81%
on 12/29/25
7.60 -7.89%
on 01/30/26
-0.15 (-2.10%)
since 11/20/25
52-Week
5.70 +22.81%
on 12/29/25
18.12 -61.37%
on 03/10/25
-10.40 (-59.77%)
since 02/20/25

Most Recent Stories

More News
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organization and drive...

MLTX : 18.77 (+3.30%)
IMA : 7.00 (+4.48%)
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced...

IMA : 7.00 (+4.48%)
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological,...

IMA : 7.00 (+4.48%)
ImageneBio CFO Resignation Announced

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

IMA : 7.00 (+4.48%)
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune...

IMA : 7.00 (+4.48%)
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc....

IKNA : 17.1600 (+4.38%)
IMA : 7.00 (+4.48%)
IIROC Trading Resumption - IMA.H

/CNW/ - Trading resumes in: Company: I-MINERALS INC. TSX-Venture Symbol: IMA.H (Formerly: IMA) Resumption (ET): 9:30 am 03/17/2023 IIROC can make a decision to...

IMA : 7.00 (+4.48%)

Business Summary

Inmagene Biopharmaceuticals is a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory diseases. The company's lead asset includes IMG-007, a nondepleting anti-OX40 monoclonal antibody. Inmagene Biopharmaceuticals, formerly...

See More

Key Turning Points

3rd Resistance Point 7.80
2nd Resistance Point 7.53
1st Resistance Point 7.26
Last Price 7.00
1st Support Level 6.72
2nd Support Level 6.45
3rd Support Level 6.18

See More

52-Week High 18.12
Fibonacci 61.8% 13.38
Fibonacci 50% 11.91
Fibonacci 38.2% 10.44
Last Price 7.00
52-Week Low 5.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar